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Abstract Berardinelli-Seip congenital lipodystrophy
(BSCL) is an uncommon autosomal recessive disorder.
Patients with BSCL present with a distinct phenotype
since subcutaneous fat is largely lacking and muscula-
ture has become more prominent. During childhood, di-
abetes and acanthosis nigricans evolve and female pa-
tients may develop hirsutism. Different genes encoding
this entity have been described. Achalasia is a rare
esophageal motility disorder, characterized by its distinct
motility pattern with absent or incomplete lower esoph-
ageal sphincter (LES) relaxations. The exact cause of
achalasia is yet unknown. Here, we describe a patient
with achalasia in the context of BSCL, which might be
linked by a shared pathophysiologic background, as
evaluated in this case report.
Conclusion: In a BSCL patient presenting with gastrointes-
tinal symptoms, a motility disorder of the gastrointestinal tract
should be considered.
What is Known:
• Berardinelli-Seip congenital lipodystrophy (BSCL) and achalasia are
both disorders characterized by low prevalence.
What is New:
• Co-existence of both diseases is described in this report. Linkage by a
potential common pathophysiologic background is discussed in this
paper.
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Introduction
Berardinelli-Seip congenital lipodystrophy (BSCL) is an au-
tosomal recessive disorder, first described by Berardinelli in
1954 and subsequently by Seip in 1959. The prevalence is
estimated to be less than 1 per 12 million people [6]. Patients
with BSCL usually present with a distinct phenotype, charac-
terized by lack of subcutaneous fat and presence of prominent
musculature. Besides, infants may present with an increased
appetite, hepatosplenomegaly, and umbilical hernia. During
childhood, diabetes as well as acanthosis nigricans evolves,
and in female patients, hirsutism may develop [7]. Mutations
in AGPAT2 (OMIM#603100) on chromosomes 9q34 [1] or
BSCL2 (OMIM#606158) on chromosome 11q12.3 [10] ac-
count for 95 % of BSCL cases [11]. AGPAT2 encodes the
enzyme acyltransferase 1-acylglycerol-3-phosphate-O-acyl-
transferase 2, involved in the cascade of the biosynthesis of
triacylglycerides and glycerophospholipids [1]. BSCL2 en-
codes the protein seipin. Mutations in this gene disrupt the
normal development and function of adipocytes and prevent
normal storage of fat in lipid droplets [3]. In a minority of
cases, biallelic mutations in one or two genes encoding major
components of the caveolae, caveol in 1 (CAV1,
OMIM#601047) [9], polymerase I and transcript release factor
(PTRF OMIM#613327), are present. Mutations in a gene
encoding an important transcription factor of adipocyte differ-
entiation, the peroxisome proliferator-activated receptor
gamma (PPARG) (OMIM#613327), may also cause BSCL
[4].
Achalasia is a rare esophageal motility disorder, character-
ized by its distinct motility pattern with absent or incomplete
lower esophageal sphincter (LES) relaxation. Typical present-
ing symptoms include dysphagia for solids and eventually
liquids, regurgitation, heartburn, and weight loss. Diagnosis
of achalasia is confirmed by performing high-resolution ma-
nometry (HRM) showing the absent or incomplete LES relax-
ations and is further classified in subtypes by different aberrant
motility patterns of the esophageal body [2]. Barium swallow
studies can be performed to show dilatation of the esophagus
or, typical for achalasia, a bird beak appearance of the distal
esophagus. The exact cause of achalasia remains to be eluci-
dated yet, but decreased or absent myenteric neurons of the
distal esophagus play a key role in the pathogenesis. Influence
of genetic and immunologic factors has also been suggested to
be involved [14]. Twin concordance seems significant, but the
nature of the genetic contribution is still inconclusive. Addi-
tionally, achalasia may present as part of genetic syndromes or
may occur in association with other abnormalities or diseases,
such as Down syndrome and Allgrove syndrome. In this case
report, we describe a patient with achalasia in the context of
BSCL.
Case report
A 14-year-old Turkish girl presented with progressive dyspha-
gia, odynophagia, regurgitation, nausea, and vomiting. Her
history revealed congenital hip dysplasia. From the age of
2 months, she had failure to thrive, despite increased appetite.
Fig. 1 Clinical picture of presented patient, demonstrating reduced
subcutaneous fat tissue
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When she was 6 years old, she was clinically diagnosed with
BSCL, because of generalized muscular hypertrophy,
macroglossia, lack of subcutaneous fat, hirsutism,
percussion-induced myoedema (localized transient swelling
of muscle induced by percussion without electrical activity
a t e lec t romyography, excluding myotonia) , and
hepatosplenomegaly. Patient was third child of not knowingly
consanguineous parents, but they originated from two close
villages. A picture of the patient, currently 18 years old, is
displayed in Fig. 1. At that time, laboratory analysis showed
elevated serum creatine kinase levels (2305 U/L), hypertri-
glyceridemia (4.6 mmol/l), and hyperinsulinism (330 pmol/l)
with normoglycemia, indicating insulin resistance. Ultrasound
of the abdomen confirmed hepatosplenomegaly with signs of
hepatic steatosis and revealed no other abnormalities. Because
of the diagnosis BSCL, a low fat with medium-chain triglyc-
erides and slow-release carbohydrates diet was prescribed.
Genetic analysis revealed no pathogenic mutations in
AGPAT2. At the age of 12 years, the diagnosis of BSCL was
reconsidered. No mutations in BSCL2, AGPAT2, or CAV1
were detected and subsequently molecular screening of PTRF
was performed. A homozygous c.258C>T transition was de-
tected in PTRF exon 1, predicting a p.Q87X nonsense muta-
tion. This mutation was found in heterozygous state in both
parents and her 15-year-old asymptomatic brother. This mu-
tation has not yet been reported in the ExAC database of 60,
000 exomes and was absent in 100 unrelated control subjects.
At time of presentation, she complained of progressive
dysphagia and vomiting. Upper esophageal series with barium
were performed under suspicion of achalasia. A dilated esoph-
ageal body, with stasis of the contrast in the esophagus, was
seen. At the esophagogastric junction, a bird’s beak deformity
was observed (Fig. 2). HRM (Manoscan360™, Given® im-
aging) showed absent and incomplete LES relaxations, with
Fig. 2 Upper esophageal series with barium, showing a dilated
esophagus body with stasis of the contrast and “bird’s beaking”
(arrow), suggestive of achalasia
Fig. 3 High-resolution manometry, showing a pressure topography plot
during a swallow. Horizontal axis corresponds with time, vertical axis
with length along the esophagus. Pressure magnitude is encoded in
colors; lower pressure regions are denoted by blue color, with
increasing pressure indicated by green to yellow colors. High-pressure
regions are denoted by red color. Continuous yellow color along the
esophagus illustrates pan-esophageal pressurization without esophageal
peristaltic contractions. Absence of LES relaxations is illustrated by a
continuous high pressure (horizontal yellow line) without a “break,”
e.g., relaxation, which is characteristic for achalasia. EGJ
esophagogastric junction, LES lower esophageal sphincter, s seconds)
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an integrated relaxation pressure (IRP) of 55.6 mmHg, above
the 15-mmHg threshold according to the Chicago classifica-
tion for achalasia in adults [2]. Peristaltic contractions of
the esophagus were absent or simultaneous (in 20 % of
swallows). Moreover, pan-esophageal pressurization and
spastic contractions were seen (Fig. 3). Based on these
typical findings on HRM, the diagnosis achalasia was
confirmed. Hence, pneumodilatation of the LES (with a
30-mm balloon) was performed with immediate relief of
the dysphagia symptoms. During later follow-up, com-
plaints of dysphagia returned and nocturnal coughing be-
came bothersome. Repeated pneumodilatations of the
LES were eventually effective, and dysphagia completely
resolved. Recently, complaints of dysphagia started to
return gradually. Meanwhile, she developed episodes of
hyperglycemia with increased HbA1c levels (up to
9.3 %) despite carbohydrate restricted diet, caused by
insulin resistance, for which metformin and Levemir
were prescribed.
Discussion
Since esophageal dilatation and weakness has previously been
observed in patients with PTRF gene mutation, it could be
hypothesized that BSCL is associated with abnormalities of
esophageal motility, like achalasia. MEDLINE was searched
using the terms congenital lipodystrophy, Berardinelli-Seip,
and achalasia (Mesh and all fields). The co-existence of BSCL
and achalasia has not yet been described in the current
literature.
In our patient, a homozygous mutation in PTRF caused
BSCL. Clinical features of patients with PTRF mutation in-
clude generalized lipodystrophy, distal myopathy, muscular
hypertrophy, percussion-induced muscle mounding
(myoedema), elevated serum creatine kinase concentration,
cardiac arrhythmias, hypertriglyceridemia, insulin resistance,
and normal intelligence. All these clinical findings, with the
exception of cardiac abnormalities, were present in our pa-
tient. PTRF plays a pivotal role in the formation of caveolae,
Fig. 4 Membrane trafficking of caveolins through exocytosis and
endocytosis. Schematic showing the itinerary of caveolin 1 (CAV1)
from synthesis in the rough endoplasmic reticulum (ER) (1) and its
trafficking through the Golgi complex (2) to the cell surface. The
cavin–PKC and casein kinase substrate in neurons 2 (PACSIN2)
complex has a vital role in stabilizing caveolae at the plasma membrane
(3). Upon endocytosis (4), caveolae can be targeted to early endosomes
and can then be recycled back to the plasma membrane or targeted to
multivesicular bodies (MVBs) for degradation (5). Targeting to MVBs
requires monoubiquitylation (monoUb) of caveolin and is valosin-
containing protein (VCP)-dependent. Non-caveolar caveolin can be
internalized through other endocytic pathways (6). Caveolin can also
traffic to lipid droplets, although the route by which this is mediated is
unclear (dashed lines) (7). Cavins may be released from caveolae into the
cytoplasm upon flattening of caveolae (8). COPII coat protein II, ILV
intralumenal vesicle, SRP signal recognition particle [12]. (printed with
permission from publisher)
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bulb-shaped invaginations of the plasma membrane. These
structures contribute to clathrin-independent endocytosis, sig-
nal transduction, as well as cholesterol transport and regula-
tion. In Fig. 4, the membrane trafficking process of caveolins
through exocytosis and endocytosis is displayed [12]. Three
types of caveolins subtypes have been identified so far: cave-
olin-1, 2, and 3. Caveolin-1 is involved in the process of bind-
ing fatty acids and their translocation into lipid droplets
[10]. Types 1 and 2 are expressed together in many cells,
including adipocytes, endothelial, and smooth muscle
cells, and type 3 in striatal (skeletal and cardiac) muscle
cells [8]. Caveolin-1 dysfunction appears to be at cause
in the alteration of lipids metabolism determining an ab-
normal profile of plasma lipids and lipoatrophy observed
in BSCL patients [9]. Sarcolemmal caveolin-3 impair-
ment secondary to the PTRF mutation is possibly at
cause of the distinctive muscle phenotype observed in
this subtype of BSCL.
Serum creatine kinase elevation appears to be an interesting
laboratory marker for diagnosis of BSCL due to PTRF
mutations [8].
So far, 21 patients with PTRF mutations have been
described in the literature. In two of these patients,
esophageal dysfunction has been described: esophageal
dilatation [8] in one case and esophageal weakness in
the other [13]. However, details of the diagnostic work-
up were not specified in the corresponding reports. Dif-
ferent hypotheses can be proposed to explain esophageal
dysfunction in the context of BSCL. First, dysfunction of
caveolin-1 might lead to alterations of the interstitial
cells of Cajal (ICC), leading to impaired function of ni-
tric oxide (NO) [5, 8]. In rats, it has been shown that
relaxation of the LES is mediated by NO. Since achalasia
patients have injured inhibitory nerves and ICC are sug-
gested to form functional units with nitrergic nerves, ICC
have been studied as potential link in the pathophysiol-
ogy of achalasia [15]. However, damage of ICC in acha-
lasia was not related to injury of nitrergic nerves and
duration of disease [16]. Perhaps, a more likely explana-
tion is found in the sustained, electrically silent muscle
contractions as part of BSCL, found also in this patient.
This would be a novel pathophysiological mechanism,
related to BSCL, which obviously needs to be confirmed
in future studies.
In conclusion, this case report describes a patient
presenting with two rare disorders, which might be
linked by a common pathophysiologic background.
However, insufficient data are currently available to ex-
plain how these two disorders are exactly related. Other
pathways, yet to be clarified, should be investigated in
further studies. In a BSCL patient presenting with gas-
trointestinal symptoms, a motility disorder of the gastro-
intestinal tract should be considered.
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